Clinical Drug Investigation

, Volume 17, Issue 2, pp 127–136 | Cite as

Pharmacokinetics of Troglitazone in Patients with Renal Insufficiency

  • Philip W. Knowlton
  • Cho-Ming Loi
  • Artemios B. Vassos
  • Robert A. Blum
  • Joanne I. Brodfuehrer
  • Edward J. Randinitis
  • Allen J. Sedman
  • Jeffrey R. Koup
Clinical Pharmacokinetics


Objective: The pharmacokinetic profiles of troglitazone and two metabolites were evaluated following a single 400mg oral dose of troglitazone in 20 patients with various degrees of renal function.

Methods: Plasma troglitazone and metabolite concentrations were determined by high performance liquid chromatography, and troglitazone free fraction was determined by ultracentrifugation.

Results: Mean maximum plasma concentration and area under the curve for total troglitazone appeared lower in patients with severe renal impairment (SRI) compared with those with normal renal function (NRF). Troglitazone free fraction was higher in patients with SRI (4.85%) than in subjects with NRF (1.66%), producing similar exposure values for unbound troglitazone, the moiety presumed to exert the pharmacological effect. Regression analysis revealed poor correlations of creatinine clearance value with total troglitazone, unbound troglitazone, and metabolite pharmacokinetic parameter values.

Conclusion: These data indicated that renal function does not predict troglitazone pharmacokinetics and systemic exposure to unbound troglitazone is unaltered with renal impairment. Thus, troglitazone dose adjustment based on pharmacokinetics is not required in patients with renal insufficiency.


Adis International Limited Normal Renal Function Troglitazone Severe Renal Impairment Clin Drug Invest 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Horikoshi H, Yoshioka T, Kawasaki T, et al. Troglitazone (CS-045), a new antidiabetic drag. Annual Report, Sankyo Research Laboratories 1994; 46: 1–57Google Scholar
  2. 2.
    Lebovitz HE, Feinglos MN. Sulfonylurea drugs: mechanism of antidiabetic action and therapeutic usefulness. Diabetes Care 1987; 1: 189–98Google Scholar
  3. 3.
    Bailey CJ, Turner RC. Metformin. N Engl J Med 1996; 334: 574–9PubMedCrossRefGoogle Scholar
  4. 4.
    Ciaraldi TP, Gilmore A, Olefsky JM, et al. In vitro studies on the action of CS-045, a new antidiabetic agent. Metabolism 1990; 39: 1056–62PubMedCrossRefGoogle Scholar
  5. 5.
    Fujiwara T, Yoshioka S, Yoshioka T, et al. Characterization of new oral antidiabetic agent CS-045: studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 1988; 37: 1549–58PubMedCrossRefGoogle Scholar
  6. 6.
    Iwamoto Y, Kuzuya T, Matsuda A, et al. Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NTDDM. Diabetes Care 1991; 14: 1083–6PubMedCrossRefGoogle Scholar
  7. 7.
    Suter SL, Nolan JJ, Wallace P, et al. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 1992; 15: 193–203PubMedCrossRefGoogle Scholar
  8. 8.
    Nolan JJ, Ludvik B, Beerdsen P, et al. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 1994; 331: 1188–93PubMedCrossRefGoogle Scholar
  9. 9.
    Loi C-M, Randinitis EJ, Vassos AB, et al. Lack of effect of type JJ diabetes on the pharmacokinetics of troglitazone in a multiple-dose study. J Clin Pharmacol 1997; 37: 1114–20PubMedGoogle Scholar
  10. 10.
    Ott P, Ranek L, Young MA. Pharmacokinetics of troglitazone, a PPAR-γ agonist, in patients with hepatic insufficiency. Eur J Pharmacol 1998; 54: 567–71CrossRefGoogle Scholar
  11. 11.
    Watkins PB, Whitcomb RW. Hepatic dysfunction associated with troglitazone. N Engl J Med 1998; 338(13): 916–7PubMedCrossRefGoogle Scholar
  12. 12.
    De Fronzo RA. Diabetic nephropathy. In: Porte Jr D and Sherwin RS, editors. Ellenberg & Rifkin’s Diabetes Mellitus. 5th ed. Stamford: Appleton & Lange, 1997: 971–1008Google Scholar
  13. 13.
    Izumi T, Enomoto S, Hosiyama K, et al. Prediction of the human pharmacokinetics of troglitazone, a new and extensively metabolized antidiabetic agent, after oral administration, with an animal scale-up approach. J Pharmacol Exp Ther 1996; 277: 1630–41PubMedGoogle Scholar
  14. 14.
    Karara AH, Frye RF, Hayes PE, et al. Pharmacokinetics of abecarnil in patients with renal insufficiency. Clin Pharmacol Ther 1996; 59: 520–8PubMedCrossRefGoogle Scholar
  15. 15.
    Rogers HJ, Savitsky JP, Glenn B, et al. Kinetics of single doses of fenbufen in patients with renal insufficiency. Clin Pharmacol Ther 1981; 29: 74–80PubMedCrossRefGoogle Scholar
  16. 16.
    Koup JR. Disease states and pharmacokinetics. J Clin Pharmacol 1989; 29: 674–9PubMedGoogle Scholar
  17. 17.
    Tozer TN. Implication of altered plasma protein binding in disease states. In: Benet LZ, editor. Pharmacokinetic basis for drug treatment. New York: Raven Press, 1984: 173Google Scholar
  18. 18.
    Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31PubMedCrossRefGoogle Scholar
  19. 19.
    Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekkar Inc., 1982Google Scholar
  20. 20.
    Loi C-M, Alvey CW, Randinitis EJ, et al. Meta-analysis of steady-state pharmacokinetics of troglitazone and its metabolites. J Clin Pharmacol 1997; 37(11): 1038–47PubMedGoogle Scholar
  21. 21.
    Young MA, Eckland DJA, Eastmond R, et al. Establishing the dose response curve for metabolic control with troglitazone, an insulin action enhancer, in type 2 diabetes patients. Ann Med 1998; 30: 206–12PubMedCrossRefGoogle Scholar
  22. 22.
    Rezulin product labeling. Physicians Desk Reference. 52nd ed. Montvale, NJ: Medical Economics Company, 1998: 2118–21Google Scholar

Copyright information

© Adis International Limited 1999

Authors and Affiliations

  • Philip W. Knowlton
    • 1
  • Cho-Ming Loi
    • 1
  • Artemios B. Vassos
    • 2
  • Robert A. Blum
    • 3
  • Joanne I. Brodfuehrer
    • 1
  • Edward J. Randinitis
    • 1
  • Allen J. Sedman
    • 2
  • Jeffrey R. Koup
    • 1
  1. 1.Department of Pharmacokinetics and Drug MetabolismParke-Davis Pharmaceutical Research DivisionAnn ArborUSA
  2. 2.Department of Clinical PharmacologyParke-Davis Pharmaceutical Research DivisionAnn ArborUSA
  3. 3.Clinical Pharmacokinetics LaboratoryMillard Fillmore HospitalBuffaloUSA

Personalised recommendations